Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On February 23, 2017, Alder BioPharmaceuticals, Inc. (Alder)
issued a press release announcing financial results for the
fourth quarter and full year ended December 31, 2016 and
providing a business update. A copy of the press release is
furnished herewith as Exhibit 99.1 and incorporated into herein
by reference.
The information in this report, including the exhibit hereto, is
being furnished and shall not be deemed filed for purposes of
Section 18 of the Securities Act of 1934, as amended, or
otherwise subject to the liabilities of that section or Sections
11 and 12(a)(2) of the Securities Act of 1933, as amended.The
information contained herein and in the accompanying exhibit
shall not be incorporated by reference into any filing with the
U.S. Securities and Exchange Commission made by Alder, whether
made before, on or after the date hereof, regardless of any
general incorporation language in such filing, except as shall be
expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release of Alder BioPharmaceuticals, Inc. issued |
About Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company’s pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone, and is being developed for the treatment of Cushing’s disease. Its candidate, Eptinezumab, is an investigational product candidate being developed as a migraine prevention treatment for patients with chronic and frequent episodic migraine. It is also is developing ALD1910, a genetically engineered monoclonal antibody. Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Recent Trading Information
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) closed its last trading session up +0.15 at 21.90 with 532,877 shares trading hands.